Scarica l'app Stockscreener
10.23
0.49%
-0.05
Precedente Chiudi:
$10.28
Aprire:
$10.22
Volume 24 ore:
1.36M
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.15B
Reddito:
-
Utile/perdita netta:
$-129.47M
Rapporto P/E:
-6.7543
EPS:
-1.5146
Flusso di cassa netto:
$-114.08M
1 W Prestazione:
-1.45%
1M Prestazione:
-16.28%
6M Prestazione:
-23.08%
1 anno Prestazione:
+118.12%
Intervallo 1D:
$10.10
$10.49
Intervallo di 1 settimana:
$9.98
$10.93
Portata 52W:
$4.52
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Nome
Oric Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 388-5600
Indirizzo
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.23 | 1.15B | 0 | -129.47M | -114.08M | -1.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-11-20 | Iniziato | Evercore ISI | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-04 | Ripresa | Guggenheim | Buy |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-10-31 | Iniziato | Wells Fargo | Overweight |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-02-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Iniziato | Wedbush | Outperform |
| 2023-03-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Perform |
| 2022-04-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-03-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-13 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Citigroup | Neutral |
| 2020-05-19 | Iniziato | Guggenheim | Buy |
| 2020-05-19 | Iniziato | JP Morgan | Overweight |
| 2020-05-19 | Iniziato | Jefferies | Buy |
Mostra tutto
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - The National Law Review
ORIC stock sees biggest intraday slump in over four years – analyst says selloff 'appears exaggerated' - MSN
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Positive Phase 1b Rinzimetostat Trial Update - Sahm
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial - Sahm
Understanding the Setup: (ORIC) and Scalable Risk - Stock Traders Daily
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation - Moomoo
Oric Pharmaceuticals Stock Rises 6.5%, Analysts Maintain Buy Ratings - National Today
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5%Still a Buy? - MarketBeat
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - Moomoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Advancing Rinzimetostat To A Phase 3 Prostate Cancer Trial - Sahm
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to - GlobeNewswire
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants - National Today
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3 - Sahm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sahm
ORIC Pharmaceuticals Faces Volatile Trading Following Latest Clinical Trial Developments - StocksToTrade
ORIC gives new employee 80,000 stock options and 15,000 RSUs - Stock Titan
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements - StocksToTrade
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements - timothysykes.com
Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Ta - GuruFocus
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - marketbeat.com
Oric Pharmaceuticals stock falls on prostate cancer trial data, Sellside Comments - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock - Investing.com
Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Target | ORIC Stock News - GuruFocus
ORIC Stock Pullback Seen as Buying Opportunity - GuruFocus
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Yahoo Finance
ORIC Pharmaceuticals Inc. R (4TZ.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What's Behind The Drop In Oric Pharmaceuticals Stock Today? - Sahm
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC: Opportunity Arises in Oric Pharmaceuticals Amid Price Drop - GuruFocus
Oric Pharmaceuticals Inc Azioni (ORIC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):